I describe a simple and intuitive method for finding sample size for clinical trials in primary breast cancer based on neoadjuvant trial results and using the FDA's patient-level meta-analysis. Then I explain a problem with this method and how the problem can be remedied. Clin Cancer Res; 22(1); 3–5.
No takes yet. Share an insight, caveat, or question.
Donald A. Berry (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: